Bio Solution Co.,Ltd. (KOSDAQ:086820)
South Korea
· Delayed Price · Currency is KRW 11,400
+330 (2.98%)
At close: Apr 27, 2026
Bio Solution Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2020 | FY 2019 |
|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Operating Revenue | 15,200 | 12,889 | 7,744 | 8,882 |
| Other Revenue | - | - | - | 0 |
| Revenue | 15,200 | 12,889 | 7,744 | 8,882 |
| Revenue Growth (YoY) | 17.93% | 66.43% | -12.81% | - |
| Cost of Revenue | 5,632 | 4,760 | 3,498 | 3,033 |
| Gross Profit | 9,568 | 8,128 | 4,246 | 5,850 |
| Selling, General & Admin | 6,616 | 6,442 | 3,541 | 3,436 |
| Research & Development | 6,306 | 5,755 | 3,230 | 3,645 |
| Amortization of Goodwill & Intangibles | 67.91 | 40.29 | 91.39 | 84.54 |
| Other Operating Expenses | 34.9 | 35.26 | 147.87 | 137.2 |
| Operating Expenses | 13,909 | 13,197 | 7,576 | 7,717 |
| Operating Income | -4,341 | -5,069 | -3,330 | -1,868 |
| Interest Expense | -2,814 | -3,133 | -40.48 | -52.6 |
| Interest & Investment Income | 387.28 | 1,496 | 1,427 | 859.13 |
| Earnings From Equity Investments | -435.58 | -2,229 | - | - |
| Currency Exchange Gain (Loss) | -10.64 | 171.48 | -15.13 | 4.03 |
| Other Non Operating Income (Expenses) | 2,613 | 1,791 | 55.51 | 12.08 |
| EBT Excluding Unusual Items | -4,600 | -6,973 | -1,903 | -1,045 |
| Gain (Loss) on Sale of Investments | 4,883 | -4,883 | 103.52 | 347.5 |
| Gain (Loss) on Sale of Assets | -1.2 | 53.69 | - | - |
| Asset Writedown | -8.44 | - | - | - |
| Other Unusual Items | - | -126.07 | - | - |
| Pretax Income | 273.36 | -11,928 | -1,800 | -697.54 |
| Net Income | 273.36 | -11,928 | -1,800 | -697.54 |
| Net Income to Common | 273.36 | -11,928 | -1,800 | -697.54 |
| Shares Outstanding (Basic) | 25 | 24 | 24 | 24 |
| Shares Outstanding (Diluted) | 25 | 24 | 24 | 24 |
| Shares Change (YoY) | 3.33% | 0.66% | 1.29% | - |
| EPS (Basic) | 11.00 | -496.00 | -75.33 | -29.57 |
| EPS (Diluted) | 11.00 | -496.00 | -75.33 | -29.67 |
| Free Cash Flow | -1,497 | -2,666 | -3,077 | -4,785 |
| Free Cash Flow Per Share | -60.22 | -110.86 | -128.79 | -202.87 |
| Gross Margin | 62.95% | 63.06% | 54.83% | 65.86% |
| Operating Margin | -28.56% | -39.33% | -43.00% | -21.03% |
| Profit Margin | 1.80% | -92.55% | -23.24% | -7.85% |
| Free Cash Flow Margin | -9.85% | -20.69% | -39.73% | -53.87% |
| EBITDA | -2,164 | -3,162 | -1,529 | -331.19 |
| EBITDA Margin | -14.24% | -24.53% | -19.75% | -3.73% |
| D&A For EBITDA | 2,177 | 1,908 | 1,800 | 1,536 |
| EBIT | -4,341 | -5,069 | -3,330 | -1,868 |
| EBIT Margin | -28.56% | -39.33% | -43.00% | -21.03% |
| Advertising Expenses | 169.22 | 192.11 | 119.42 | 89.35 |
Source: S&P Capital IQ. Standard template. Financial Sources.